Table 1.

Patient characteristics

	All patients, n (%)
Patients, n	26
Age at infusion, years (range)	14.4 (4.0-24.5)
Male	15 (58)
Follow-up, d (range)	389 (53-800)
MRD-negative CR on d 28	20 (77)
Indication for CAR T therapy
Primary refractory	4 (15)
Relapse	22 (85)
Disease status at start of lymphodepletion
M1 marrow	17 (65)
≥M2 marrow	9 (35)
Prior lines of systemic therapy, n
1-2	21 (81)
3-5	5 (19)
Prior blinatumomab
Yes	7 (27)
No	19 (73)
Prior allo-HCT
Yes	11 (42)
No	15 (58)
TP53 mutation
Yes	2 (8)
No	24 (92)